Novartis commences Phase III trial for ASA404
Novartis Inc has initiated the Phase III trial for its non-small cell lung cancer drug, ASA404, designed to selectively reduce blood supply to tumors. The randomized, double-blind, placebo-controlled, multicenter study, named ATTRACT-1, is designed to evaluate ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic non-small cell lung cancer.
- Everolimus trials show benefit in kidney cancer
- Novartis kidney cancer drug shows promise
- FDA grants priority review to RAD001
- Agennix Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally
